ASSESSMENT OF THE DEVELOPMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE BY CLINICAL AND LABORATORY MARKERS

Currently, non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases in hepatology, leading to a deterioration in the quality of life, disability and death. The overall prevalence of NAFLD in the population ranges from 10 to 40% [1,3,5,6,7]. In the normal course of NAFLD, 12-40% of patients with hepatosis develop non-alcoholic steatohepatitis after 8-13 years. Of these, 15% of patients develop liver cirrhosis and liver failure. Of 7% of patients with liver cirrhosis, hepatocellular carcinoma develops within 10 years [2,3,5]. The heterogeneity of NAFLD leads to the absence of a single generally accepted standard of treatment for such patients. Of course, all overweight patients should be advised to reduce their weight by eating a low-calorie diet and exercising regularly, and the effect of the latter seems to be more significant. An unhealthy lifestyle is the main cause of NAFLD [3,4,5,8]